摘要
目的探究多奈哌齐对阿尔茨海默病(AD)的远期疗效和安全性。方法选取2013年5月至2015年1月来佳木斯大学附属第一医院就诊的AD患者96例,按抽签法分为研究组和对照组,各48例。研究组给予多奈哌齐每次5 mg、每日1次治疗;对照组给予氢溴酸加兰他敏每次8 mg、每日2次,与早餐及晚餐同服进行治疗。比较两组患者治疗后6个月的临床疗效,记录治疗前、治疗3个月及6个月的简易智能精神状态量表(MMSE)、日常生活活动能力量表(ADL)和老年性痴呆评定量表-认知分量表(ADAS-cog)评分以及治疗后的不良反应情况。结果研究组患者的远期总有效率明显高于对照组[89.6%(44/48)比75.0%(36/48)](P<0.05)。两组治疗3个月、治疗6个月MMSE评分均较治疗前呈上升趋势,且研究组上升速度更快,两组在组间、时点间、组间·时点间交互作用差异有统计学意义(P<0.05);治疗3个月及6个月后,两组ADL评分较治疗前均上升趋势,且研究组上升速度更快;ADAS-cog评分较治疗前均呈下降趋势,且研究组下降速度更快。两组在组间、时点间、组间·时点间交互作用差异有统计学意义(P<0.05)。治疗6个月两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论多奈哌齐能够提高AD的远期治疗效果,显著改善AD患者的生活质量,且与服用氢溴酸加兰他敏相比并未提高不良反应发生率。
Objective To explore long-term efficacy and safety of donepezil in patients with Alzheimer′s disease(AD). Methods From May 2013 to Jan.2015,96 AD patients admitted to the First Affiliated Hospital of Jiamusi University for treatment were divided into a study group and a control group according to sortation method ,48 cases each .The study group was given donepezil ,5 mg/time,1 time/day, the control group was given galanthamine hydrobromide ,8 mg/time,2 times/day,at bedtime.The mini-mental status estimate(MMSE),the activities of daily life(ADL),Alzheimer′s disease assessment cognition scale(ADAS-cog)and adverse reactions of the two groups were detected before treatment ,3 months and 6 months after treatment.Results Long term efficacy of the study group was significantly higher than that of the control group [(89.6%(44/48) vs 75.0%(36/48)](P<0.05).MMSE scores of two groups after 3 and 6 months of treatment all raised than before treatment ,and the study group increased faster .The differences between groups , different time points , interaction of groups · time points were statistically significant ( P<0.05 );ADL scores increased in both groups after 3 and 6 months of treatment , faster in the study group .ADAS-cog scores of both groups all declined after 3 and 6 months of treat-ment than before treatment , and the study group declined faster .The differences between groups , different time points , interaction of groups · time points were statistically significant ( P<0.05 ) .After 6 months of treatment adverse reactions between the two groups showed no significant difference ( P>0.05 ) .Conclusion Donepezil can effectively improve living quality and enhance long-term efficacy of patients with AD .Compared with the galanthamine hydrobromide , donepezil doesn′t improve the adverse reaction rate .
出处
《医学综述》
2017年第2期-,共4页
Medical Recapitulate
关键词
阿尔茨海默病
多奈哌齐
远期疗效
不良反应
Alzheimer′s disease
Donepezil
Long-term efficacy
Adverse reactions
